Nightfood Holdings Inc. (OTCQB: NGTF), operating through its TechForce Robotics subsidiary, announced the advancement of Phase 2 objectives under its joint development collaboration with Oncotelic Therapeutics (OTCQB: OTLC). The milestone is highlighted by the deployment of PUR-E, an autonomous clean room support robot, within SAPU Bio’s OEB-5 sterile injectable cGMP facility. This deployment expands the initiative beyond Phase 1 materials logistics operations into sterile manufacturing and clean room environments, where TechForce and Oncotelic are evaluating robotics, automation and AI-driven technologies to support regulated pharmaceutical workflows.
PUR-E joins TechForce’s LIM-E autonomous GMP support robot at the SAPU Bio facility, where the systems are being used to assess opportunities in sterile manufacturing operations, electronic batch record processes and other cGMP activities. According to the companies, the initiative is part of a broader effort to develop robotics and automation solutions for pharmaceutical manufacturing, biotechnology and life sciences environments, with PUR-E operating as part of TechForce’s Robotics-as-a-Service Provider (RaaSP) platform. The integration of these robots aims to improve operational efficiency, workflow consistency, and labor optimization in highly regulated environments.
This development is significant for the pharmaceutical industry, as it addresses critical challenges in sterile manufacturing, including contamination risk, human error, and labor shortages. By deploying autonomous systems in OEB-5 facilities—which handle highly potent compounds—TechForce and Oncotelic are pioneering the use of robotics in environments that demand the highest levels of safety and precision. The electronic batch record processes enabled by these robots can also enhance data integrity and regulatory compliance, potentially reducing costs and speeding up production timelines.
Nightfood Holdings, doing business as TechForce Robotics, is an AI-enhanced robotics and automation company focused on multiple industries, including hospitality, foodservice, commercial, laboratory, pharmaceutical, and emerging enterprise automation environments. The company delivers its solutions through a Robotics-as-a-Service (RaaS) model, providing flexible, scalable automation while generating recurring revenue. As it expands into pharmaceutical automation and other high-precision applications, it leverages strategic partnerships like the one with Oncotelic to accelerate innovation.
The collaboration with Oncotelic and the deployment at SAPU Bio underscore the growing trend of automation in life sciences. For investors, this move signals Nightfood’s commitment to diversifying its robotics applications beyond foodservice into high-growth pharmaceutical markets. The full press release can be viewed at https://ibn.fm/mXU1p. More information about Nightfood Holdings is available in the company’s newsroom at http://ibn.fm/NGTF.
